Take­da builds ar­se­nal for im­muno-on­col­o­gy re­search, cre­ates cell ther­a­py group

Take­da’s pres­ence in can­cer — for­ti­fied by its $5.2 bil­lion Ari­ad buy­out — is grow­ing, as it an­nounced a range of agree­ments in im­muno-on­col­o­gy and the cre­ation of a cell ther­a­py unit, days be­fore the Japan­ese drug­mak­er con­sum­mates its $62 bil­lion takeover of Dublin-based Shire.

Take­da, whose main list­ing is in Tokyo but re­cent­ly be­gan al­so trad­ing on the NYSE un­der the sym­bol $TAK, is col­lab­o­rat­ing with the Memo­r­i­al Sloan Ket­ter­ing Can­cer Cen­ter’s Michel Sade­lain, who serves as di­rec­tor of MSK’s Cen­ter for Cell En­gi­neer­ing and is al­so the sci­en­tif­ic founder of Juno Ther­a­peu­tics, to de­vel­op CAR-T ther­a­pies for mul­ti­ple myelo­ma, acute myeloid leukemia and ad­di­tion­al sol­id tu­mor in­di­ca­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER